Insiders Updates
Wells Fargo upgrades Regulus Therapeutics Inc (RGLS) rating to an Overweight
In a filing, Regulus Therapeutics Inc revealed its President & Head of R & D Klassen Preston acquired Company’s shares
Menu
In a filing, Regulus Therapeutics Inc revealed its President & Head of R & D Klassen Preston acquired Company’s shares
Regulus Therapeutics Inc’s filing revealed that its President & Head of R & D Klassen Preston acquired Company’s shares for
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
In a filing, Regulus Therapeutics Inc revealed its President & Head of R & D Klassen Preston acquired Company’s shares
Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Regulus Therapeutics
Regulus Therapeutics Inc. (RGLS) shares gained 15.69% to $1.92 in Monday’s early session after reporting positive clinical trial results. A